Dyne Therapeutics, Inc. DYN R2K
Healthcare · Biotechnology · United States
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.
READ MORE ›$19.33
+61.62% 1Y
Market & Price
Market Cap
$3.20B
Current Price
$19.33
High / Low (52W)
$24.29 / $8.18
Beta
1.08
Valuation
Stock P/E
-
Industry PE
23.65
Forward P/E
-
PEG Ratio
-
Book Value
$5.89
Price to Book
3.28
P/S
-
EV/EBITDA
-5.10
Dividend Yield
-
Profitability & Returns
ROCE
-38.72%
ROE
-58.89%
ROA
-32.70%
Profit Margin
0.00%
Op Margin
0.00%
EPS (Latest Qtr)
$-0.73
EPS (TTM)
$-3.15
Balance Sheet & Liquidity
Debt/Equity
0.19
Quick Ratio
18.97
Current Ratio
19.92
Debt
$168.68M
Total Assets
$1.19B
Current Assets
$1.13B
Working Capital
$1.08B
Ownership
Promoter Holding
0.28%
Chg in Prom Hold
0.00%
FII / Inst Holding
115.46%
Chg in FII Hold
-0.02%
Financial Snapshot
Enterprise Value
$2.39B
Total Revenue (TTM)
-
EBITDA
$-468.99M
Free Cash Flow
$-292.28M
Operating Cash Flow
$-442.24M
Shares Outstanding
165.31M
Gross Margin
0.00%
Payout Ratio
0.00%
Growth (CAGR)
Revenue 5Y
-
Profit 5Y
-55.15%
Revenue (YoY)
-
Earnings (YoY)
-
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Earnings shrank at -55.1% CAGR over 5 years.
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | DYN Dyne Therapeutics, Inc. R2K | 19.33 | - | $3.20B | - | -38.72% | -58.89% | - | -55.15% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Ad space
Quarterly Results
Figures in USD.
| Metric | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 122.37M | 115.79M | 113.89M | 116.13M | 125.28M |
| Operating Income | - | - | -3.63M | -7.85M | -8.68M | -13.52M | -25.13M | -30.16M | -42.77M | -35.78M | -52.76M | -42.28M | -45.46M | -66.74M | -62.27M | -69.16M | -71.96M | -105.57M | -122.37M | -115.79M | -113.89M | -116.13M | -125.28M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -114.86M | -110.26M | -104.61M | -108.24M | -116.10M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 94.00K | 2.90M | 3.19M | 4.20M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -115.36M | -110.86M | -108.04M | -111.95M | -120.85M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -2.09M | -1.50M | -5.87M | -7.89M | -8.98M | -13.92M | -24.97M | -29.95M | -42.58M | -35.58M | -52.30M | -41.38M | -44.19M | -64.90M | -60.21M | -65.65M | -65.10M | -97.12M | -115.36M | -110.86M | -108.04M | -111.95M | -120.85M |
| Diluted EPS | - | - | - | - | - | - | - | -0.58 | -0.83 | -0.69 | -1.01 | -0.80 | -0.78 | -1.08 | -0.99 | -0.81 | -0.70 | -0.96 | -1.05 | -0.97 | -0.76 | -0.76 | -0.73 |
| R&D Expense | - | - | 2.98M | 6.09M | 7.33M | 9.68M | 18.62M | 23.87M | 36.51M | 28.24M | 46.66M | 34.67M | 37.54M | 59.13M | 55.25M | 44.54M | 62.26M | 92.80M | 106.45M | 99.24M | 97.22M | - | 100.89M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | 170.96M | 242.16M | 343.89M | 468.18M |
| Operating Income | -13.83M | -58.65M | - | -170.96M | -242.16M | -343.89M | -468.18M |
| EBITDA | - | - | - | -169.28M | -234.26M | -315.75M | -437.97M |
| Interest Expense | - | - | 0 | - | 0 | 0 | 6.19M |
| Pretax Income | - | - | - | -168.10M | -235.94M | -317.42M | -446.21M |
| Tax Provision | - | - | - | - | - | - | - |
| Net Income | -14.86M | -59.44M | - | -168.10M | -235.94M | -317.42M | -446.21M |
| Diluted EPS | - | - | -2.93 | -3.23 | -3.95 | -3.37 | - |
| R&D Expense | 11.04M | 45.20M | 121.31M | 142.76M | 210.76M | 281.41M | 398.33M |
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | - |
Compounded Profit Growth
| 5 Years: | -55.15% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +61.62% |
| 6 Months: | -7.07% |
| 3 Months: | +23.75% |
| 1 Month: | +11.03% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 16.44M | 353.33M | - | 306.32M | 165.08M | 691.23M | 1.19B |
| Current Assets | - | - | - | - | 265.59M | 129.38M | 659.28M | 1.13B |
| Cash & Equivalents | - | 14.63M | 300.85M | - | 172.15M | 121.63M | 435.45M | 893.37M |
| Inventory | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - | - |
| Total Liabilities | - | 2.40M | 10.97M | - | 53.96M | 73.79M | 61.40M | 214.83M |
| Current Liabilities | - | 2.36M | 10.97M | - | 28.09M | 51.09M | 42.26M | 50.62M |
| Long Term Debt | - | - | - | - | - | - | - | 148.92M |
| Total Debt | - | - | - | - | 30.48M | 27.41M | 23.99M | 169.20M |
| Total Equity | -4.88M | 14.04M | 342.37M | - | 252.36M | 91.29M | 629.84M | 972.13M |
| Shares Outstanding | - | - | - | - | 55.64M | 61.47M | 102.32M | 164.95M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -11.83M | -46.51M | - | -153.65M | -188.16M | -292.37M | -403.21M |
| Investing Cash Flow | -1.65M | -45.66M | - | 87.20M | 83.31M | -204.08M | -28.75M |
| Financing Cash Flow | 19.99M | 380.69M | - | 37.39M | 54.32M | 809.89M | 890.31M |
| Capital Expenditure | -1.65M | -1.16M | - | -3.07M | -729.00K | -2.38M | -20.71M |
| Free Cash Flow | -13.48M | -47.67M | - | -156.71M | -188.89M | -294.75M | -423.92M |
| Net Change in Cash | - | - | - | -29.05M | -50.52M | 313.45M | 458.35M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - | - |
| ROE % | -105.9% | -17.4% | - | -66.6% | -258.4% | -50.4% | -45.9% |
| ROCE % | -98.2% | -17.1% | - | -61.4% | -212.4% | -53.0% | -41.2% |
Shareholding Pattern
Insiders
0.28%
Institutions
115.46%
Public Float
115.78%
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | T. Rowe Price Investment Management, Inc. | 18.62% | 30.79M | $595.09M |
| 2 | Janus Henderson Group PLC | 8.26% | 13.65M | $263.80M |
| 3 | Blackrock Inc. | 7.08% | 11.70M | $226.16M |
| 4 | Atlas Venture Life Science Advisors, LLC | 5.52% | 9.13M | $176.49M |
| 5 | FMR, LLC | 5.39% | 8.91M | $172.21M |
| 6 | Orbis Allan Gray Ltd | 4.09% | 6.76M | $130.71M |
| 7 | State Street Corporation | 4.02% | 6.65M | $128.62M |
| 8 | Vanguard Capital Management LLC | 3.87% | 6.41M | $123.81M |
| 9 | Perceptive Advisors Llc | 2.82% | 4.67M | $90.25M |
| 10 | FCPM III Services B.V. | 2.81% | 4.64M | $89.78M |
Analyst View
Loading analyst coverage…
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for DYN
No recent headlines available.